- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Preclinical Model to Guide Immunotherapeutic Development
Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.
Nov. 18-21
Barcelona, Spain
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26th EORTC-NCI-AACR Symposium, held in , discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions' TumorGrafts® in guiding clinical development strategy.
Keren Paz
"There continues to be a need for improved models that enable researchers to better understand the clinical potential of therapeutics early in their development, ideally in the preclinical setting," said , Ph.D., chief scientific officer of Champions Oncology. "The findings presented at EORTC-NCI-AACR continue to demonstrate the advantages of our TumorGraft platform and our ability to create personalized mouse models for the exciting new class of immuno-oncology therapeutics. We look forward to presenting future case studies with our ImmunoGrafts at additional conferences in the year ahead."
Read the complete press release: http://prn.to/1F3F4M8
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
